Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.96
(
-0.45%
)
Bitcoin
70,732.71
(
1.19%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 98716

Sunday, 10/31/2010 10:50:56 PM

Sunday, October 31, 2010 10:50:56 PM

Post# of 257262
JNJ/Medivir report that 79-86% of TMC435 patients in the four non-control arms of the phase-2b PILLAR study in the first-line setting stopped treatment at 24 weeks according to the response-guided protocol in the study:

http://finance.yahoo.com/news/Week24-Interim-Results-From-prnews-47168379.html?x=0&.v=1

The protocol of this study required that patients have undetectable VL from week 4 to week 20 in order to stop treatment at 24 weeks.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now